RESMED
RESMED operates in Diversified Metals & Mining.
RESMED (RME) - Net Assets
Latest net assets as of September 2024: €5.20 Billion EUR
Based on the latest financial reports, RESMED (RME) has net assets worth €5.20 Billion EUR as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€7.22 Billion) and total liabilities (€2.03 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €5.20 Billion |
| % of Total Assets | 71.93% |
| Annual Growth Rate | 14.09% |
| 5-Year Change | 94.79% |
| 10-Year Change | N/A |
| Growth Volatility | 7.11 |
RESMED - Net Assets Trend (2016–2024)
This chart illustrates how RESMED's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for RESMED (2016–2024)
The table below shows the annual net assets of RESMED from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | €4.86 Billion | +17.78% |
| 2023-06-30 | €4.13 Billion | +22.89% |
| 2022-06-30 | €3.36 Billion | +16.46% |
| 2021-06-30 | €2.89 Billion | +15.56% |
| 2020-06-30 | €2.50 Billion | +20.50% |
| 2019-06-30 | €2.07 Billion | +0.64% |
| 2018-06-30 | €2.06 Billion | +5.04% |
| 2017-06-30 | €1.96 Billion | +15.66% |
| 2016-06-30 | €1.69 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to RESMED's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 131.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €4.99 Billion | 102.62% |
| Total Equity | €4.86 Billion | 100.00% |
RESMED Competitors by Market Cap
The table below lists competitors of RESMED ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Versus Systems Inc
NASDAQ:VS
|
$1.97 Million |
|
ASSURANT
BE:ZAS
|
$1.97 Million |
|
My Size Inc
NASDAQ:MYSZ
|
$1.97 Million |
|
Nevada Exploration Inc
OTCQB:NVDEF
|
$1.97 Million |
|
Verena Multi Finance Tbk
JK:VRNA
|
$1.97 Million |
|
Trillium Gold Mines Inc
OTCQX:TGLDF
|
$1.97 Million |
|
Birks Group Inc
NYSE MKT:BGI
|
$1.97 Million |
|
GHST World Inc
PINK:GHST
|
$1.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in RESMED's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,129,903,000 to 4,864,043,000, a change of 734,140,000 (17.8%).
- Net income of 1,020,951,000 contributed positively to equity growth.
- Dividend payments of 282,320,000 reduced retained earnings.
- Share repurchases of 150,011,000 reduced equity.
- New share issuances of 53,094,000 increased equity.
- Other factors increased equity by 92,426,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €1.02 Billion | +20.99% |
| Dividends Paid | €282.32 Million | -5.8% |
| Share Repurchases | €150.01 Million | -3.08% |
| Share Issuances | €53.09 Million | +1.09% |
| Other Changes | €92.43 Million | +1.9% |
| Total Change | €- | 17.78% |
Book Value vs Market Value Analysis
This analysis compares RESMED's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.14x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 14.75x to 6.14x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-06-30 | €13.79 | €203.35 | x |
| 2018-06-30 | €14.43 | €203.35 | x |
| 2019-06-30 | €14.42 | €203.35 | x |
| 2020-06-30 | €17.23 | €203.35 | x |
| 2021-06-30 | €19.81 | €203.35 | x |
| 2022-06-30 | €22.95 | €203.35 | x |
| 2023-06-30 | €28.08 | €203.35 | x |
| 2024-06-30 | €33.11 | €203.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently RESMED utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 20.99%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 21.79%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 1.41x
- Recent ROE (20.99%) is above the historical average (20.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 20.79% | 19.17% | 0.56x | 1.92x | €182.93 Million |
| 2017 | 17.46% | 16.56% | 0.60x | 1.77x | €146.26 Million |
| 2018 | 15.33% | 13.49% | 0.76x | 1.49x | €109.69 Million |
| 2019 | 19.52% | 15.52% | 0.63x | 1.98x | €197.37 Million |
| 2020 | 24.90% | 21.02% | 0.64x | 1.84x | €371.97 Million |
| 2021 | 16.44% | 14.84% | 0.68x | 1.64x | €185.94 Million |
| 2022 | 23.19% | 21.78% | 0.70x | 1.52x | €443.36 Million |
| 2023 | 21.73% | 21.25% | 0.63x | 1.63x | €484.57 Million |
| 2024 | 20.99% | 21.79% | 0.68x | 1.41x | €534.55 Million |
Industry Comparison
This section compares RESMED's net assets metrics with peer companies in the Other industry.
Industry Context
- Industry: Other
- Average net assets among peers: $114,212,818,724
- Average return on equity (ROE) among peers: -9.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| RESMED (RME) | €5.20 Billion | 20.79% | 0.39x | $1.97 Million |
| HORIBA (01H) | $204.49 Billion | 10.42% | 0.82x | $989.01K |
| Tokyu Corporation (01T) | $779.37 Billion | 3.34% | 2.35x | $99.73K |
| GUANGZHOU AUTO -H- (02G) | $122.28 Billion | 6.59% | 0.55x | $4.05K |
| MOSAIC (02M) | $10.60 Billion | 4.43% | 0.90x | $280.83K |
| MOSAIC (02M.SG) (02M) | $9.56 Billion | 10.46% | 0.82x | $247.21K |
| CHINA JO-JO DRGSTRS (04CN.SG) (04CN) | $16.67 Million | -126.83% | 4.46x | $1.55 Million |
| KRAKATAU STEEL -B- (07K) | $552.59 Million | 3.52% | 4.72x | $166.99 |
| CN MODERN DAIRY (07M) | $7.12 Billion | -10.42% | 1.50x | $1.68K |
| TOURMALINE OIL (08T) | $7.22 Billion | 4.81% | 0.41x | $381.02K |
| ASIA CASSAVA RESOUR (0ACS) | $913.15 Million | 2.86% | 1.55x | $325.03 |